Evidence map›Paper›PMID 35252842›Full record

ArticleTransportation research interdisciplinary perspectives2022

Half-hearted policies on mobility restrictions during COVID-19 in Indonesia: A portrait of large informal economy country.

Khoirunurrofik Khoirunurrofik, Faris Abdurrachman, Lovina Aisha Malika Putri

Abstract read
In one paragraph

Article in Transportation research interdisciplinary perspectives, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Khoirunurrofik KhoirunurrofikInstitute for Economic and Social Research, Universitas Indonesia, Indonesia.
Faris AbdurrachmanInstitute for Economic and Social Research, Universitas Indonesia, Indonesia.
Lovina Aisha Malika PutriInstitute for Economic and Social Research, Universitas Indonesia, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study measures the effectiveness of government's transportation policy on mobility restriction during the COVID-19 pandemic using publicly available big datasets. Using a causal difference-in-difference (DiD) analysis and regression discontinuity design (RDD), we examine the impact of non-pharmaceutical interventions (NPIs) on the aggregate population mobility of cities and regencies across Indonesia. Our results show that during the period of the first so-called "Large-scale Social Restrictions" or "Pembatasan Sosial Berskala Besar" (PSBB I) from April to May 2020, NPIs reduced mobility by 5.4% relative to pre-pandemic baseline and accounted for a small portion of mobility decline in cities or regencies that instituted mobility restrictions. The impact of the second PSBB policy (PSBB II) from September to November 2020 was smaller, with a mobility reduction of only 1.8%-2.9%, depending on the window of observation and sample. Lastly, the "Imposition of Restriction on Social Activity" or Pemberlakuan Pembatasan Kegiatan Masyarakat (PPKM) policy beginning in January 2021 has had a more negligible impact, with mobility reduction of approximately 0.6-2.1%. These findings indicate that the effectiveness of mobility restrictions tend to decrease over time. The decline in effectiveness may be the result of the increased cost of social distancing over long periods of time and the declining stringency of the mobility restrictions being imposed, which may be particularly pronounced for emerging countries with a large informal sector, such as Indonesia.

Indexed as

COVID-19Difference-in-differencesIndonesiaMobility restrictionPolicy evaluationPopulation mobility

Identifiers

PMID35252842
PMCPMC8884077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.